Collectively, these results show that BRD4 inhibition prevents cell proliferation and EMT, and exerts an antitumor effect in RCC by activating the NF-κB–NLRP3–caspase-1 pyroptosis signaling pathway. The gene discussed is NFKB1; the disease is renal cell carcinoma.